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The performance ofafluorescence imaging devicewascomparedwith conventional white-lightbron-
choscopy in 100 patients with lung cancer, 46 patients with resected stage non-small cell lung can-
cer, l0 patients with head and neck cancer, and 67 volunteers who had smoked at least pack of
cigarettes per day for 25 years or more. Using differences in tissue autofluorescence btween pre-
malignant, malignant, and normal tissues, fluorescence bronchoscopy was found to detect signifi-
cantly more areas with moderate/severe dysplasia or carcinoma in situ than conventional white-light
bronchoscopy with a similar specificity. Multiple foci of dysplasia or cancer were found in 13-24%
of these individuals. Fluorescence bronchoscopy may be an important adjunct to conventional bron-
choscopic examination to improve our ability to detect and localize premalignant and early lung can-
cer lesions.
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INTRODUCTION
The best results ofphotodynamic therapy (PDT) for lung
cancer are seen in patients with carcinoma in situ or mi-
croinvasive cancers. Complete eradication of these early
lung cancer lesions without loss of normal lung tissue or
lung function capacity can be seen in over 90% of these
patients (Hayata et al., 1993; Furuse et al., 1993; Edell
andCortese, 1992).Whenprecancerous lesions are found,
chemoprevention agents, such as 13-cis-retinoic acid or
Retinol can be used to regress the lesions (Lippman et al.,
1990, Pastorino et al., 1993). Despite the availability of
these treatment modalities, very few patients benefit from
them because dysplasia and early lung cancer lesions are
very difficult to detect and localize with conventional
white-light bronchoscopic examination. In a study by
Woolner and coworkers (Woolner et al., 1984), only 29%
of carcinoma in situ (CIS) were visible to an experienced
endoscopist. Even for pathologists who had the opportu-
nity to carefully examine the resected specimens, they
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were able to visualize the site of the CIS lesions in only
41% of the cases (Woolner et al., 1984). In an attempt to
overcome this problem, a lung imaging fluorescence en-
doscopic (LIFE) device was developed to detect precan-
cerous and CIS lesions using differences in tissue
autofluorescence between normal and abnormal tissues
(Hung et al., 1991; Lain et al., 1993; Palcic et al., 1991;
Lain and Palcic, 1993).
The objective of this study was to determine if fluores-
cence bronchoscopy using the LIFE device can improve
the ability of conventional white-light bronchoscopy to
detect bronchial dysplasia and CIS.
MATERIALS AND METHODS
Life
LIFE is comprised of a helium-cadmium laser as a light
source (442 nm), two image-intensified CCD cameras
with green (520 nm) and red (>630 nm) filters, respec-
tively, acomputerwithanimagingboard,andacolorvideo
monitor (Lam and Palcic, 1993). Two images at different
(red and green) wavelengths are simultaneously captured
in precise registration by the imaging board. The images76 S. LAM et al.
are then combined and processed by an imaging board
using a specially developed algorithm that allows normal
tissue to be clearly distinguished from malignant tissue
when displayed as apseudocolorimage on the videomon-
itor. The computed image is displayed in real time (at
video rates). The detection oflung tumors is based on the
observation that tumors in vivo have considerably lower
autofluorescence in the green than normal tissue, while
emission in the red is similar (not as reduced) (Hung et
al., 1991). The computed image is independent of the dis-
tance between the bronchoscope tip and the bronchial
wall. The processed image can be displayed as desired,
for example, normal tissue as green and tumor as brown
or brownish red (Fig. 1A and B). An abnormal area can
be biopsied under direct vision for pathologic confirma-
tion.
SUBJECTS
Four groups of subjects were studied. Group I consisted
of 100 patients with lung cancer(age63 _+ 9 years, male/fe-
male, 67/33). The pathology of the primary lung cancer
was squamous 50%, adenocarcinoma 25%, large cell car-
cinoma 16%, small cell carcinoma 7%, and 2% other
tumor types. Group II consisted of46 patients with stage
I completely resected lung cancer (age 66 9 years,
male/female, 34/12). Group III consisted of 10 patients
with head and neck cancer (age 62 10 years, all males).
Group IV consisted of 67 volunteers who had smoked
more than 1 packofcigarettes perday for 25 years ormore
(age 56 _
8 years), male/female, 51/16). There were 48
current smokers and 19 ex-smokers. They had smoked an
average of 50 +_ 27 pack years.
Figure IA Left upper lobe under white-light bronchoscopy, no
abnormality as found.
CLINICAL PROTOCOL
Conventional fiberoptic bronchoscopy was performed
with patients under local anesthesia. White-light exami-
nation was first done with an Olympus BF20D fiberoptic
bronchoscope. Areas suspected of dysplasia or cancer
were recorded and noted as such for subsequent biopsy.
Fluorescence bronchoscopy with the LIFE device was
then carried out biopsy specimens for pathologic exami-
nation were taken of all abnormal areas discovered by the
white-light or the fluorescence examination, or both. In
addition, two or more random biopsies were done in the
visually (white-light and fluorescence) normal areas. On
the average, the fluorescence examination and extra biop-
sies added another 5 to 10 minutes to a standard fiberop-
tic bronchoscopic procedure.
This study was approved by the Clinical Investigations
Review Committee of the University of British Columbia
and the British Columbia Cancer Agency.
Figure IB Same areaas 1A underfluorescence imaging with theLIFE
device. A small area of carcinoma in situ was found. Autofluorescence
from normal bronchial tissue was represented by green color. Carcinoma
in situ appeared reddish-brown.
Table I Prevalence of Dysplasia and Carcinomas in situ
No. of Dsplasia Carcinoma
Group subjects Moderate Severe In Situ
>2
Foci
100 14% 11% 15% 15%
II 46 18% 4% 13% 24%
III 10 20% 10% 10% 20%
IV 67 36% 15% 5% 13%
Group Known/suspected lung cancer; group II stage completely resected lung cancer,
group III head and neck cancer; group IV volunteer smokers.EARLY LOCALIZATION OF BRONCHOGENIC CARCINOMA 77
Table 2 Bronchoscopy and Biopsy Results
Fluorescence Fluorescence Fluorescence
White
Light
+
275 33
18 12
Normal/Inflamed
White 15 33 White 3 18
Light Light
+ 6 24 + 0 14
Moderate/severe Carcinoma in situ
Dysplasia
DATA ANALYSES
The principle objective of this study was to measure the
increase in detection rate for moderate dysplasia or worse
achieved by the addition of LIFE to white-light bron-
choscopy using the bronchial biopsy pathology as the
"gold" standard. The positive rates among the two modes
of examination were compared using the X2 test. The
specificity of white light versus fluorescence bron-
choscopy was also compared.
RESULTS
From the 223 subjects, 338 biopsies were found to have
anormal/inflamedhistopathology, 78 biopsieswerefound
to show moderate or severe dysplasia and 35 were found
to have carcinoma in situ.
The prevalence of dysplasia and carcinoma in situ in
the four study groups are shown in Table 1.
Ofthe CIS lesions thatwere detectedby white-light ex-
amination, 84% were superficial and 16% were nodu-
lar/polyploid.
The proportion ofbiopsy proven moderate/severe dys-
plasia, and CIS detected by white-light bronchoscopy
alone was 38.5% and 40%, respectively. With the addi-
tion ofLIFE examination, the detection rate was 73.1 and
91.4% respectively. The specificity of white-light brow
choscopy was 91.1%. With fluorescence bronchoscopy,
the specificity was 86.7% (Table 2).
DISCUSSION
Dysplasia and carcinoma in situ are difficult to detect by
conventionalbronchoscopybecause these lesions are only
a few cell layers thick (0.2 to 1 ram) and a few millime-
ters in surface diameter (Hayata et al., 1993; Woolner et
al., 1984; Woolner 1983; Nagamoto et al., 1986). Because
of this, they may not produce any visible abnormality on
conventional white-lightbronchoscopy.The superficial or
flat type of early lung cancer usually presents as areas of
paleness, roughness, redness, microgranularity, or loss of
luster in the surface mucosa. The mucosal folds or
bronchial bifurcation may appear to be swollen or thick-
ened with the loss of clarity. They are not usually de-
tectable by bronchoscopy until they are 0.5 cm or more in
diameter(Hayata etal., 1993; Nagamoto et al., 1986). The
nodular or polypoid type ofearly lung cancer usually pre-
sents as an area of protrusion. Nodular lesions are easier
to detect because they are elevated from the adjacent nor-
mal mucosa. Lesions as small as 0.2 cm can be detected
by white-light bronchoscopy (Hayata et al., 1993;
Nagamoto et al., 1986). The bronchoscopic appearance
of bronchial dysplasia has not been carefully studied. In
this study, thedysplastic lesions thatwere visibleon white-
light bronchoscopy presented as focal thickening of the
mucosal fold or bifurcation. Overall, 40% of the dysplas-
tic lesions or CIS were visible by white-light examina-
tion. Since the bronchoscope only serves as a means to
examine the surface of a body cavity, it is unlikely that
furtheradvances in white-lightbronchoscopycanimprove
our ability to detect pre-cancerous lesions or early cancer.
Our study suggests that instead of making use of the re-
fleeted/scattered light, one can use light induced tissue
autofluorescence to improve the detection rate of these
early lung cancer lesions by more than two times with a
similar specificity.
The results in this study are similartoourprevious study
involving 94 subjects where we observed a sensitivity of
72.5% for fluorescence bronchoscopy in detecting mod-
erate/severe dysplasia and carcinoma in situ with a speci-
ficit of 94%. Using white light bronchoscopy, the
sensitivity was 48.4% with the same specificity (Lam et
a/., 1993). In both studies, false-positives were due to in-
flammatio in the submucosa or squamous metaplasia re-
sulting in swellingorthickeningofthemucosa.Thereason
for the false-negative sites (3/35 CIS lesions) was not
clear. All three tumors regressed spontaneously on fol-
low-up. It is possible that in situ carcinomas with nonag-
gressivebiologicalbehaviorhave differentreflectanceand
fluorescence properties.78 S. LAMet al.
The concept offluorescence detection has intrigued the
minds ofmany since the beginning of the twentieth cen-
tury. In 1924, Policard observed that in an experimental
model of sarcoma, the tumor tissue fluoresced red upon
illumination by Wood’s light (Policard, 1924). In 1933,
Sutro and Burman observed that when surgically excised
breast tissue was exposed to Wood’s light, normal breast
tissue fluoresced green, while breast cancer tissues fluo-
resced purple (Sutro ar. Burman, 1993). These observa-
tions were confirmed by others in cancer of the skin and
mouth in addition to breast cancer (Ronchese, 1954). Red
fluorescence was found to be associated with advanced
cancers only (Ronchese, 1954). The color of the natural
tissue autofluorescence induced by filtered ultraviolet
light is variable and in addition, the emitted light is ofvery
low intensity. For these reasons, it has been very difficult
to observe it visually, and therefore, almost all of the re-
search in fluorescence bronchoscopy since the 1960s em-
ployed exogenous fluorescent compounds to enhance
humans ability to detect early lung cancer. It was not until
the advent of image-intensified cameras and computer
image processing technologies that tissue autofiuores-
cence alone could be used for detecting small thin early
cancers and premalignant lesions.
Synchronous or second primary cancers occur com-
monly in patients with lung cancer. An autopsy study of
Auerbachandco-workersshowedthatin patientswhodied
of lung cancer, CIS could be found in 15% of these pa-
tients (Auerbach et al., 1961). In the same study, in smok-
ers who died ofnon-lung cancer causes, CIS was found in
4.3% of those who smoked 1-2 packs per day and 11.4%
of those who smoked more than 2 packs a day (Auerbach
et al., 1961). In patients resected stage I lung cancer, sec-
ond primary tumors occur in 10-20% of cases (Pastorino
et al., 1993; Thomas et al., 1990; Cortese, et al., 1983).
The prevalence of dysplasia and CIS observed in our pa-
tients with lung cancer and in the smoking volunteers are
consistent with the findings in these earlier studies.
Our study suggests that fluorescence bronchoscopy, in
conjunction with standard white-lightbronchoscopy, may
be very useful in the detection ofsynchronous and second
primary tumors in patients with lung cancer. In high risk
populations such as heavy smokers, fluorescence bron-
choscopy may also be useful for localizing precancerous
lesions and CIS. This technology, in combination with
local treatments such as photodynamic therapy which can
eradicate these lesions without lossofnormal lung tissues,
offers hope that the traditionally poor prognosis of lung
cancer may be altered in a significant way.
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